THERAPEUTIC DRUG MONITORING OF INFLIXIMAB IN SPONDYLOARTHRITIS. A REVIEW OF THE LITERATURE.
Br J Clin Pharmacol. 2019 Jul 17;:
Authors: Fobelo Lozano MJ, Serrano Giménez R, Sánchez Fidalgo S
Available evidence indicates that a therapeutic drug monitoring (TDM) strategy leads to major cost savings related to the anti-tumour necrosis factor-α (TNF-α) therapy in both inflammatory bowel disease and rheumatoid arthritis (RA) patients1 , with no negative impact on efficacy. However, although the systematic use of TDM could potentially be beneficial and economically acceptable to drug dose optimization, it is not justifiable for all drugs. Infliximab (IFX) is a chimeric monoclonal immunoglobulin G1 (IgG1) targeting TNF. It has been approved for the treatment of immuno-inflammatory diseases, including RA, ankylosing spondylitis (AS), psoriatic arthritis (PsA), Crohn’s disease (CD) and ulcerative colitis (UC). IFX’s pharmacokinetics is highly variable and influences clinical response in chronic inflammatory diseases2 . Clinical response increases with IFX through concentrations in RA3-5 , AS6 , IBD and psoriatic patients7 . Target concentrations predictive of good clinical response were proposed in RA8 , CD9 and UC10 . The purpose of this article is to review the current literature surrounding IFX serum concentrations and their related parameters with disease activity in patients with spondyloarthritis (SA). Gathering information about the efficacy of IFX in patients with SA and relating IFX serum concentrations to disease activity were the main goals of this study.
PMID: 31315147 [PubMed – as supplied by publisher]